Evidence map›Paper›PMID 41542082›Full record

ReviewComputational and structural biotechnology journal2025

The role of super-enhancer-driven lncRNAs in cancer.

Yuan-Ying Su, Fang-Yuan Ji, Ze-Jun Zheng, Jiang-Yun Peng, Jian-Jun Xie

Abstract readReview
In one paragraph

Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuan-Ying SuLab1, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan 523808, PR China.
Fang-Yuan JiInstitute of Biochemistry & Molecular Biology, Institute of Aging Research, Guangdong Medical University, Dongguan 523808, PR China.
Ze-Jun ZhengLab1, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan 523808, PR China.
Jiang-Yun PengInstitute of Biochemistry & Molecular Biology, Institute of Aging Research, Guangdong Medical University, Dongguan 523808, PR China.
Jian-Jun XieLab1, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan 523808, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the global burden of cancer has grown substantially, yet available treatments and clinical outcomes remain inadequate. Accordingly, research into novel therapeutic targets for cancer has become a major focus. Super-enhancers (SEs), which are clusters of multiple enhancers, represent essential epigenetic oncogenic factors that are critical for maintaining cancer cell identity. Moreover, SE-driven long non-coding RNAs (lncRNAs) play a crucial regulatory role in tumor initiation and progression. Targeting cancer-specific SE-driven lncRNAs can slow tumor development and offer a novel strategy for cancer treatment. This review first outlines the characteristics of SEs, including their relevance to phase separation (PS) and the core transcriptional regulatory circuitry (CRC). It then describes the fundamental characteristics, intracellular localization, and functions of SE-driven lncRNAs, with emphasis on the analytical methods for these lncRNAs and their roles in tumors. Finally, the review highlights the clinical applications of existing SE inhibitors in oncology and their potential for targeting SE-driven lncRNAs, aiming to advance translational research in this field.

Indexed as

Cancer therapyLong non-coding RNAsSuper-enhancers

Identifiers

PMID41542082
PMCPMC12799938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.